Cancer Care

 

 

Comprehensive Breast Program Clinical Trials

A clinical trial is one of the final steps in a long and careful cancer research process that is looking for better ways to prevent, diagnose, or treat cancer. Clinical trials test new medical approaches in patients with cancer, and are important to developing new treatments for cancer. Many of the "standard treatments" that patients with cancer receive today were developed based on the results of previous clinical trials.

The following is a list of clinical trials with which this cancer care program is currently involved. Talk to your doctor to find out if a clinical trial is right for you.

Breast-Female Clinical Trials
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
Breast-Female
E1Z11
Schwartz
A Phase I Dose Escalation Study of POL6326 with Eribulin in Patients with Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer
Breast-Female
F14043
Kaufman
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Breast-Female
NSABP B-43
Larmon
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Breast-Female
NSABP-B43M
Manno
A Phase III Randomized Double-Blind Study of Letrozole vs. Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen
Breast-Female
C49805
Kaufman
A Phase III Trial Of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost For Early-Stage Breast Cancer
Breast-Female
R1005
Hartford
A Phase III, Open Label, Randomized, Controlled, Multi-Centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy versus Physician's Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations
Breast-Female
F14083
Arrick
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Breast-Female
S1007
Chamberlin
A Prospective Study of Partial Breast Adjuvant Radiation Therapy After Resection of Borderline and Malignant Phyllodes Tumors
Breast-Female
D0929
Barth
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Breast-Female
NSABP-B55
Arrick
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Breast-Female
R1304
Hartford
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Breast-Female
NSABP-B47
Chamberlin
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Breast-Female
F14056
Kaufman
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
Breast-Female
E2108
Schwartz
A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab plus Pertuzumab plus a Taxane Following Anthracyclines versus Trastuzumab Emtansine plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer
Breast-Female
F14005
Kaufman
A Study to Evaluate the use of Supine MRI Images in Breast Conserving Surgery
Breast-Female
D0928
Barth
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER2+) Metastatic Breast Cancer
Breast-Female
F12189
Kaufman
Cyclophosphamide and Doxorubicin (CA x 4 Cycles) Versus Paclitaxel (4 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-­3 Positive Axillary Lymph Nodes: A Phase III Randomized Study
Breast-Female
C40101
Kaufman
IBCSG-24-02: A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT)
Breast-Female
C-SOFT
Kaufman
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
Breast-Female
Z11102
Rosenkranz
Low Dose Metronomic Cyclophosphamide and Methotrexate Chemotherapy in Combination with Aspirin in Patients with Stage II-III Breast Cancer Who Fail to Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy
Breast-Female
SFD12054
Chamberlin
Participation Restrictions in Young-Middle Adult Rural Breast Cancer Survivors
Breast-Female
D1032
Hegel
Phase II Placebo-Controlled Trial of Lisinopril and Coreg CR® to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (Neo)Adjuvant Chemotherapy with Trastuzumab (Herceptin®)
Breast-Female
SCUSF0806
Schwartz
Phase III Study of Adriamycin/Taxotere vs Adriamycin/Cytoxan for the Adjuvant Treatment of Node Positive or High Risk Node Negative Breast Cancer
Breast-Female
C49802
Kaufman
Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer
Breast-Female
S0221
Schwartz
Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel with or without Trastuzumab as Adjuvant Treatment for Women with HER-2 Overexpressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer
Breast-Female
C49909
Kaufman
Presurgical treatment with letrozole in patients with early-stage breast cancer
Breast-Female
D13236
Schwartz
Reducing Disparities in Health for Vulnerable Populations in NH and VT: Journey Forward Cancer Survivor Care Planning in the Rural Northeast
Breast-Female
FED11061
Pace
The Effect of a Goal Setting Intervention on Exercise in Women with Metastatic Breast Cancer: An Exploration of the Lipogenic Pathway
Breast-Female
D11282
Chamberlin
Tumor Specific Plasma DNA in Breast Cancer
Breast-Female
D12127
Schwartz
Breast-Male Clinical Trials
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Breast-Male
NSABP-B55
Arrick
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
Breast-Male
E2108
Schwartz
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER2+) Metastatic Breast Cancer
Breast-Male
F12189
Kaufman
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
Breast-Male
Z11102
Rosenkranz
Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer
Breast-Male
S0221
Schwartz
Reducing Disparities in Health for Vulnerable Populations in NH and VT: Journey Forward Cancer Survivor Care Planning in the Rural Northeast
Breast-Male
FED11061
Pace